Guidances are "not binding," FDA emphasizes in response to Indiana group's petition.
This article was originally published in The Tan Sheet
Executive Summary
FDA'S EXISTING POLICY APPEALS MECHANISMS EMPHASIZED in a preliminary agency response to a May citizen petition from the Indiana Medical Device Manufacturing Council (IMDMC) that asked FDA to take steps to eliminate so-called "informal rulemaking." In an Oct. 30 letter to attorney Bradley Thompson of the Indianapolis firm Baker & Daniels, which submitted the petition on behalf of IMDMC, FDA Deputy Commissioner for Policy William Schultz highlighted several existing mechanisms companies can use to appeal FDA actions they believe to be based on inappropriate application of guidance documents or other informal policy statements.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning